These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17160207)

  • 1. [Treatment of Paget's disease of bone: importance of the zoledronic acid].
    Griz L; Colares V; Bandeira F
    Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):845-51. PubMed ID: 17160207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM; Scott LJ
    Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
    Gennari L; Merlotti D; Mossetti G; Rendina D; De Paola V; Martini G; Nuti R
    Mini Rev Med Chem; 2009 Aug; 9(9):1052-63. PubMed ID: 19689402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
    Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid for treatment of Paget's disease of bone.
    Devogelaer JP; Manicourt DH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2863-9. PubMed ID: 17956205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of zoledronic acid for Paget's disease of bone.
    Maricic M
    Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid for Paget's disease of bone.
    Maricic M
    Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
    Conesa Mateos A; Rotés Sala D; Almirall Bernabé M; Carbonell Abelló J
    Med Clin (Barc); 2006 Oct; 127(16):635-6. PubMed ID: 17145033
    [No Abstract]   [Full Text] [Related]  

  • 10. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
    Polyzos SA; Anastasilakis AD; Anagnostis P; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
    Endokrynol Pol; 2012; 63(4):312-5. PubMed ID: 22933168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D
    Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone.
    Polyzos SA
    Clin Rheumatol; 2011 Jan; 30(1):149-50. PubMed ID: 21053036
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
    Reid IR; Maslowski K
    Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Paget's disease of bone with zoledronic acid].
    Body JJ; Sternon J
    Rev Med Brux; 2005; 26(6):513-7. PubMed ID: 16454155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paget's disease of bone: diagnosis and treatment].
    Winter EM; Hamdy NA; de Jongh RT; Eekhoff EM; Zillikens MC; Appelman-Dijkstra NM
    Ned Tijdschr Geneeskd; 2016; 160():D254. PubMed ID: 27650015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
    Arden-Cordone M; Siris ES; Lyles KW; Knieriem A; Newton RA; Schaffer V; Zelenakas K
    Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of a single dose of zoledronic acid in a case of Paget bone disease].
    Saban M; Fidalgo S; Díaz CA; Lutfi RJ
    Medicina (B Aires); 2010; 70(5):445-8. PubMed ID: 20920964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronate treatment in active Paget's disease.
    Chung G; Keen RW
    Ann Rheum Dis; 2003 Mar; 62(3):275-6. PubMed ID: 12594123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.